Protalix BioTherapeutics, Inc. (PLX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 22.02M | 2.03M | -3.73M | -5.23M | -5.06M | 3.99M | 4.11M | -3.61M | 4.19M | 3.6M | -6.89M | 4.97M |
| Operating CF Margin % | 65.26% | 22.25% | -20.91% | -33.42% | -50.01% | 21.91% | 22.86% | -26.79% | 111.74% | 34.28% | -66.58% | 14.18% |
| Operating CF Growth % | 535.45% | -49.14% | -190.91% | -44.96% | -220.77% | 11.02% | 159.6% | -172.59% | 239.69% | 237.69% | 25.16% | 167.6% |
| Net Income | 18.32M | 1.1M | 2.35M | 164K | -3.62M | 6.49M | 3.24M | -2.2M | -4.59M | -6.04M | -1.85M | 19.34M |
| Depreciation & Amortization | 404K | -1.08M | 372K | 360K | 346K | 334K | 329K | 319K | 322K | 372K | 305K | 293K |
| Stock-Based Compensation | 532K | -1.56M | 598K | 427K | 540K | 654K | 620K | 998K | 981K | 1.37M | 1.1M | 438K |
| Deferred Taxes | 71K | -177K | 59K | 231K | -113K | 0 | 443K | -69K | -138K | 0 | 38K | -3.13M |
| Other Non-Cash Items | 163K | -2.03M | 20K | 484K | -372K | -44K | 1.15M | -503K | -466K | 1.6M | -407K | -425K |
| Working Capital Changes | 2.54M | 5.78M | -7.14M | -6.9M | -1.84M | -3.45M | -1.67M | -2.15M | 8.08M | 6.3M | -6.07M | -11.54M |
| Change in Receivables | 0 | 0 | -4.85M | -4.64M | -2.27M | -752K | 0 | -7.05M | 1.75M | 3.76M | -4.31M | -3.7M |
| Change in Inventory | -4.75M | -4.47M | -124K | -1.63M | 1.74M | -4.04M | 3.52M | 1.63M | -3.3M | 2.54M | -1.95M | 668K |
| Change in Payables | 820K | 4.33M | 0 | 0 | 0 | 0 | -869K | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 4.22M | -1.11M | -504K | -438K | -312K | -15.32M | 20.33M | -180K | -606K | -342K | -20.88M | -222K |
| Capital Expenditures | -761K | 1.24M | -498K | -431K | -306K | -425K | -87K | -172K | -598K | -250K | -447K | -204K |
| CapEx % of Revenue | 2.25% | 13.54% | 2.79% | 2.75% | 3.03% | 2.33% | 0.48% | 1.28% | 15.96% | 2.38% | 4.32% | 0.58% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 3K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 4.98M | -2.35M | -6K | -7K | -6K | -14.89M | 20.41M | -8K | -8K | -92K | -20.43M | -18K |
| Cash from Financing | 150K | 146K | 0 | 4.1M | 5.08M | 3.63M | -20.42M | 0 | 0 | 0 | 0 | 10.43M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -20.42M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 150K | 146K | 0 | 3.95M | 2.86M | 3.63M | 0 | 0 | 0 | 0 | 0 | 9.72M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 153K | 2.21M | 0 | 0 | 0 | 0 | 0 | 0 | 712K |
| Net Change in Cash | 26.32M | 1.74M | -4.25M | -1.56M | -302K | -7.65M | 4.01M | -3.81M | 3.58M | 3.23M | -27.78M | 15.15M |
| Free Cash Flow | 21.26M | 3.27M | -4.23M | -5.66M | -5.36M | 3.57M | 4.02M | -3.78M | 3.59M | 3.35M | -7.33M | 4.77M |
| FCF Margin % | 63% | 35.79% | -23.7% | -36.17% | -53.04% | 19.57% | 22.37% | -28.07% | 95.78% | 31.9% | -70.9% | 13.6% |
| FCF Growth % | 496.42% | -8.44% | -205.28% | -49.76% | -249.41% | 6.61% | 154.78% | -179.3% | 210.6% | 218.45% | 20.81% | 163.72% |
| FCF per Share | 0.26 | 0.04 | -0.05 | -0.07 | -0.07 | 0.04 | 0.05 | -0.05 | 0.05 | 0.05 | -0.09 | 0.06 |
| FCF Conversion (FCF/Net Income) | 1.20x | -0.37x | -1.58x | -31.91x | 1.40x | 0.61x | 1.27x | 1.64x | -0.91x | -0.59x | 3.72x | 0.26x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 766K | -1K | 766K | 899K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |